Avoro Capital Advisors LLC 13D and 13G filings for Spyre Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 09:35 am Sale | 2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE | Avoro Capital Advisors LLC | 885,059 1.700% | -954,079 (-51.88%) | Filing |
| 2024-04-23 6:22 pm Sale | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Avoro Capital Advisors LLC | 1,839,138 5.100% | -286,459 (-13.48%) | Filing |
| 2024-02-14 09:08 am Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Avoro Capital Advisors LLC | 2,125,597 5.900% | 2,125,597 (New Position) | Filing |